Cover Image
市場調查報告書

成骨不全症:開發中產品分析

Osteogenesis Imperfecta - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 465221
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
成骨不全症:開發中產品分析 Osteogenesis Imperfecta - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 49 Pages
簡介

成骨不全(OI)是一種遺傳性疾病,其特徵在於骨骼容易因為極少或無明顯原因而破裂。這種疾病是由於形成骨骼的蛋白質之第一型膠原蛋白基因受損或缺陷所引起。症狀包括骨骼畸形,多重骨折,關節鬆動,牙齒脆弱,心臟缺陷和呼吸問題。治療包括雙磷酸鹽(骨吸收抑制劑)和手術。

本報告提供成骨不全症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

成骨不全症;概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發中產品
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amgen Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Mereo Biopharma Group Plc

藥物簡介

  • ALLOB
  • BPS-804
  • cannabidiol
  • denosumab
  • fresolimumab
  • KAL-436/9

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10219IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2018, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteogenesis Imperfecta - Overview
    • Osteogenesis Imperfecta - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Osteogenesis Imperfecta - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Bone Therapeutics SA
    • Genzyme Corp
    • Mereo Biopharma Group Plc
  • Osteogenesis Imperfecta - Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fresolimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAL-436 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAL-439 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setrusumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Osteogenesis Imperfecta - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta
      • May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease
      • Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
      • Jun 30, 2016: Mereo's BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
      • Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
      • Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Osteogenesis Imperfecta, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Osteogenesis Imperfecta - Pipeline by Amgen Inc, H1 2018
  • Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H1 2018
  • Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H1 2018
  • Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H1 2018

List of Figures

  • Number of Products under Development for Osteogenesis Imperfecta, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top